Elicio Therapeutics (ELTX) Earnings Analysis

Elicio Therapeutics (ELTX) next reports earnings on 2026-08-06, consensus EPS -0.53 USD. Last quarter (2026-05-11) it missed with EPS -0.65 USD vs -0.49 USD est (-32.7%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -1.32.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ELTX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.53 USD
Revenue estimaten/a

ELTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.65 USD-0.49 USD-32.7%Miss
2026-03-12-0.49 USD-0.47 USD-4.3%Miss
2025-11-13-0.6 USD-0.62 USD+3.2%Beat
2025-03-31-1.02 USD-0.94 USD-8.5%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

ELTX valuation and analyst view

Trailing P/E-1.32
Trailing EPS-2.20654 USD
Price / book-39.54
Dividend yield0.00%
Market cap0.06B
Analyst consensusHold (1 buy / 2 hold / 0 sell)
Avg price target17 USD

Related research pages

Frequently asked questions

When is Elicio Therapeutics (ELTX)'s next earnings date?

Elicio Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.53 USD.

Did ELTX beat earnings last quarter?

In its 2026-05-11 report, ELTX posted EPS of -0.65 USD versus a -0.49 USD estimate — a miss of 32.7%.

What is ELTX's earnings track record?

Over the last 4 reported quarters with consensus data, ELTX beat estimates 1 times (25%).

What is ELTX's current P/E ratio and EPS?

ELTX trades at a trailing P/E of -1.32 on trailing EPS of -2.206543085245263 USD.

What do analysts rate ELTX?

Analyst consensus is "Hold" across 3 ratings (0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.